PF-07202954 is an orally active, highly selective DGAT2 inhibitor with an IC 50 of 10 nM against human DGAT2 and an IC 50 of 17 nM against rat DGAT2 . PF-07202954 reduces triglyceride synthesis, decreases hepatic triglyceride content and plasma triglyceride levels, inhibits de novo lipogenesis, and suppresses the hepatic SREBP signaling pathway as well as the expression of SREBP target genes. PF-07202954 is applicable to research related to non-alcoholic steatohepatitis.
Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Acyltransferase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.